A new way to deliver anti-cancer antibodies for better treatment
The resurgence of antibody-drug conjugates via PMPC-polymer engineering
This research explores a new way to deliver anti-cancer antibodies more effectively throughout the body, including hard-to-reach areas like the brain, to fight cancers like B-cell lymphomas.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11133043 on NIH RePORTER |
What this research studies
Many antibody treatments for cancer face challenges in reaching all tumor cells or staying active in the body for a long time. This project is developing a new delivery system using a special polymer called PMPC to enhance how therapeutic antibodies work. This system helps antibodies circulate longer, reach specific cancer locations more effectively, including difficult areas like the brain and lymph nodes, and protects them from being cleared too quickly. The goal is to make anti-cancer antibodies much more potent and effective against various cancers, including those that have spread to challenging areas.
Who could benefit from this research
Good fit: Patients with certain cancers, such as B-cell lymphomas or HER2-positive cancers, who might benefit from more targeted and potent antibody therapies, could be ideal candidates for future clinical applications of this research.
Not a fit: Patients whose cancers do not respond to antibody therapies or who have conditions incompatible with this specific polymer-based delivery system may not receive direct benefit from this particular approach.
Why it matters
Potential benefit: If successful, this new delivery method could lead to more effective treatments for various cancers, especially those that have spread to difficult-to-reach areas like the brain or lymph nodes.
How similar studies have performed: This approach builds on patented technology and has shown promising results in animal models, with initial steps toward clinical translation already underway.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Kamata, Masakazu — University of Alabama at Birmingham
- Study coordinator: Kamata, Masakazu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.